company background image
4RY logo

Akeso DB:4RY Stock Report

Last Price

€7.35

Market Cap

€6.7b

7D

-3.3%

1Y

n/a

Updated

22 Dec, 2024

Data

Company Financials +

My Notes

Capture your thoughts, links and company narrative

Akeso, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Akeso
Historical stock prices
Current Share PriceHK$7.35
52 Week HighHK$9.45
52 Week LowHK$3.60
Beta0.54
1 Month Change-15.52%
3 Month Change2.80%
1 Year Changen/a
3 Year Change99.73%
5 Year Changen/a
Change since IPO124.32%

Recent News & Updates

Recent updates

Shareholder Returns

4RYDE BiotechsDE Market
7D-3.3%-2.9%-2.6%
1Yn/a-14.7%6.9%

Return vs Industry: Insufficient data to determine how 4RY performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 4RY performed against the German Market.

Price Volatility

Is 4RY's price volatile compared to industry and market?
4RY volatility
4RY Average Weekly Movement10.0%
Biotechs Industry Average Movement6.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 4RY's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 4RY's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20122,815Michelle Xiawww.akesobio.com

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK105, a PD-1 monoclonal antibody to treat classic Hodgkin’s lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors.

Akeso, Inc. Fundamentals Summary

How do Akeso's earnings and revenue compare to its market cap?
4RY fundamental statistics
Market cap€6.73b
Earnings (TTM)-€96.59m
Revenue (TTM)€246.18m

27.3x

P/S Ratio

-69.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4RY income statement (TTM)
RevenueCN¥1.87b
Cost of RevenueCN¥146.05m
Gross ProfitCN¥1.73b
Other ExpensesCN¥2.46b
Earnings-CN¥735.33m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.82
Gross Margin92.21%
Net Profit Margin-39.24%
Debt/Equity Ratio64.2%

How did 4RY perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 13:24
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Akeso, Inc. is covered by 38 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yonglin YanBOCI Research Ltd.
Sharon ShiBOCI Research Ltd.
Jiangqiao TongBOCI Research Ltd.